Mylan shares to rebound more than 20 percent as EpiPen debacle ends: Top analyst

Mylan EpiPen
Drew Angerer | Getty Images

Top-ranked analyst Irina Koffler of Mizuho Securities on Wednesday initiated shares of Mylan with a buy rating, citing an attractive valuation and the potential for the company to recover from the EpiPen pricing debacle.

"We view MYL as oversold due to recent uncertainty about the EpiPen franchise and management concerns, and we expect shares to recover once the company provides more visibility and guidance. Additionally, there are a number of potential catalysts that could drive share momentum over the next six months," Koffler wrote in a research note.

Her picks have a 17 percent one-year average return, according to analyst ranking service TipRanks, placing her in the top 2 percent of all Wall Street analysts covering any industry.

More In Pro News and Analysis

CNBC ProHere’s how top international fund managers are navigating Covid spikes, chip shortages
CNBC ProThe stock market continues to keep sellers at bay, offering few reasons to fight the tape
CNBC ProThese stocks are ready to rally as the earnings recovery kicks in, analysts say